Piracetam relieves symptoms in progressive myoclonus epilepsy: A multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo

Journal of Neurology Neurosurgery and Psychiatry

Volumn 64, Issue 3, 1998, Pages 344-348

  Koskiniemi, Marjaleena ^a   Van Vleymen, Betty ^b   Hakamies, Lauri ^c   Lamusuo, Salla ^d   Taalas, Jaakko ^e  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UCB PHARMA   (Belgium)

^c VAASA CENTRAL HOSPITAL   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e MIKKELI CENTRAL HOSPITAL   (Finland)

Author keywords

Double blind; Myoclonus; Piracetam; Progressive myoclonus epilepsy

Indexed keywords

PIRACETAM;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; CROSSOVER PROCEDURE; DEPRESSION; DISABILITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HANDWRITING; HEADACHE; HUMAN; HYPERKALEMIA; HYPERNATREMIA; LEG EDEMA; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; MYOCLONUS EPILEPSY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEIZURE; SLEEP DISORDER; STIMULUS RESPONSE; TREATMENT OUTCOME; VERTIGO;

ACTIVITIES OF DAILY LIVING; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CROSS-OVER STUDIES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EPILEPSIES, MYOCLONIC; FEMALE; HANDWRITING; HUMANS; LINEAR MODELS; MALE; MOTOR SKILLS; NEUROPROTECTIVE AGENTS; PIRACETAM; SEVERITY OF ILLNESS INDEX;

EID: 0031920926     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.64.3.344     Document Type: Article

References (34)

1. Aigner BR, Mulder DW. Mypclonus, clinical significance and an approach to classification. Arch Neurol 1960;2:600-15.
2. Berkovic S, Andermann F, Carpenter S, Wolfe L. Progressive myoclonus epilepsies: specific causes and diagnosis. N Engl J Med 1986;31:296-304.
3. Marseille Consensus Group. Classification of progressive myoclonus epilepsies and related disorders. Ann Neurol 1990;28:113-6.
4. Norio R, Koskiniemi M. Progressive myoclonus epilepsy; genetic and nosological aspects with special reference to 107 Finnish patients. Clin Genet 1979;15:382-98.
5. Unverricht H. Über familiare Myoclonie. Dtsch Z Nervenheilk 1895;7:32-67.
6. Van Heycop Ten Ham MW, Jager de H. Progressive myoclonus epilepsy with Lafora bodies. Clinicalpathological features. Epilepsia (Amsterdam) 1963;4:95-119.
7. Koskiniemi M, Donner M, Majuri H, Haltia M, Norio R. Progressive myoclonus epilepsy: a clinical and histopathologic study. Acta Neurol Scand 1974a;50:307-32.
8. Eldridge R, Iivanainen M, Stern R, Koerber T, Wilder BJ. 'Baltic' myoclonus epilepsy: hereditary disorder of childhood made worse by phenytoin. Lancet 1983;ii:838-12.
9. Pennacchio LA, Lehesjoki A-E, Stone NE, et al. Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPMI). Science 1996;271:1731-4.
10. Lehesjoki A-E, Koskiniemi M, Pandolfo M, et al. Linkage studies in progressive myoclonus epilepsy: Unverricht-Lundborg and Lafora diseases. Neurology 1992;42:1545-50.
11. Lehesjoki A-E, Eldridge R, Eldridge J, Wilder BJ, de la Chapelle A. Progressive rayoclonus epilepsy of Unverricht-Lundborg type: a clinical and molecular genetic study of a family from the United States with four affected sibs. Neurology 1993;43:2384-6.
12. Malafosse A, Lehesjoki A-E, Genton P, et al. Identical genetic locus for Baltic and Mediterranean myoclonus. Lancet 1992;i:1080-1.
13. Goldberg MA, Dorman JD. Intention myoclonus: successful treatment with clonazepam. Neurology 1976;26:24-6.
14. Fahn S. Posthypoxic action myoclonus: review of the literature and report of two new cases with response to valproate and estrogen. Adv Neurol 1979;26:49-84.
15. Iivanainen M, Himberg JJ. Valproate and clonazepam in the treatment of severe progressive myoclonus epilepsy. Arch Neurol 1982;39:236-8.
16. Meador K, Loring D, Huh K, Gallagher B, King D. Comparative cognitive effects of anticonvulsants. Neurology 1990;40:391-4.
17. Koskiniemi M. Progressive myoclonus epilepsies. In: PJ Vinken and GW Bruyn, eds. Handbook of clinical neurology. Amsterdam: Elsevier, 1997 (in press).
18. Fahn S. Newer drugs for posthypoxic action myoclonus: observations from a well-studied case. Adv Neurol 1986;43: 197-9.
19. Remy C, Genton P. Effect of high dose of oral piracetam on myoclonus in progressive myoclonus epilepsy (Mediteranean myoclonus). Epilepsia 1991;32(suppl 3):6.
20. Obeso JA, Artieda J, Quinn M, Rothwell JC, Luquin MR, Vaamonde J, Marsden CD. Piracetam in the treatment of different types of myoclonus. Clin Neuropharmacol 1988;11: 529-36.
21. Brown P, Steiger MJ, Thompson PD, et al. Effectiveness of piracetam in cortical myoclonus. Mov Disord 1993;8:63-8.
22. Jones B, Kenward M. Design and analysis of cross-over trials. London: Chapman and Hall, 1989:1-352.
23. Senn S. Cross-over trials in clinical research. New York: Wiley, 1993:1-266.
24. Pigeon JG, Raghavarao D. Crossover designs for comparing treatments with a control. Biometrika 1987;74:321-8.
25. Truong DD, Fahn S. Therapeutic trial with glycine in myoclonus. Mov Disord 1988;3:222-32.
26. Israel L, Melac M, Milinkevitch D, Dubos G. Drug therapy and memory training programs. A double-blind randomised trial of general practice patients with age-associated memory impairment (AAM). Int Psychogeriatr 1994;6:155-70.
27. Croisile B, Trillet M, Fondarai J, Laurent B, Mauguiére F, Billardon M. Long-term and high-dose piracetam treatment of Alzheimer's disease. Neurology 1993;43:301-5.
28. Bente D, Glatthaar G, Ulrich G, Lewinski M. Piracetam and vigilance, a study of EEG changes and clinical effects in gerontopsychiatric patients. Drug Research 1988;28:1529-30.
29. Wilsher CR, Bennett D, Chase CH, et al. Piracetam and dyslexia: effects on reading tests. J Clin Psychopharmacol 1987;7:230-7.
30. Levinson HN. Dramatic favorable responses of children with learning disabilities or dyslexia and attention deficit disorder to antimotion sickness medications: four case reports. Percept Mot Skills 1991;73:723-38.
31. Müller WE, Koch S, Scheuer K, Rostock A, Bartsch R. Effects of piracetam on membrane fluidity in the aged mouse, rat and human brain. Biochem Pharmacol 1997;53: 135-40.
32. Peuvot J, Schanck A, Deleers M, Brasseur R. Piracetam-induced changes to membrane physical properties. Biochem Pharmacol 1995;50:1129-34.
33. Bick RL. In vivo platelet inhibition by piracetam [letter]. Lancet 1979;8145:752-3.
34. Artieda J, Obeso JA, Luquin MR, Vaamonde J, Martinez-Lage JM. Piracetam in the treatment of myoclonus of various origin. Neurology 1986; 36(suppl 1):277.